Empagliflozin for heart failure annual sales hefref?

What were empagliflozin (Jardiance) annual sales in heart failure?

I don’t have the specific “annual sales for heart failure” figures in the provided information. Empagliflozin’s revenue is typically reported as total product sales (Jardiance) rather than split into “heart failure” only, unless a company discloses segment-by-indication numbers.

What number do you usually mean by “annual sales”?

People may mean one of these:
- Total global sales of Jardiance (empagliflozin) per year
- Sales tied specifically to heart failure patients/indication (if disclosed)
- A regional breakdown (US vs EU vs Japan) or quarter-by-quarter sales

If you share which format you want (global vs US, and whether you need indication-specific heart failure sales or total Jardiance sales), I can target the right figure.

What does empagliflozin’s heart-failure use cover (and why that matters for sales attribution)?

Empagliflozin is used for heart failure in multiple clinical contexts (with reduced and preserved ejection fraction), and brands may report revenues across those uses together. Without indication-level reporting, “heart failure sales” often can’t be determined precisely from public revenue totals alone.

Tell me what you’re looking for (so I can give the right sales figure)

Reply with:
1) Do you want total Jardiance (empagliflozin) sales or heart-failure-only sales?
2) Which geography (global, US, EU, etc.)?
3) Which year (e.g., 2023, 2024)?
4) Do you want the number in USD or EUR?

Once you confirm, I can provide the closest matching annual sales figure.